Curis Reports Dosing Of First Patient In Phase 1 Trial Of CUDC-907; FUJIFILM Completes Acquisition Of Kalon Biotherapeutics
December 19, 2014 at 05:03 AM EST
CRIS, a drug development company announced that the first patient has been treated in a Phase I clinical study of CUDC-907. (FDBU), a FUJIFILM Corporation subsidiary, today announced the completion of its acquisition of Kalon Biotherapeutics LLC.
